At the close of ACT I the IFAA team will report all findings – including successes & failures of having patients in leadership roles, recommended revisions to retest procedures, & hypothesize how patient inclusion could lead to time & budget savings. It will also conclude ways patients, industry, & researchers visualize productive partnerships & will propose an expansion to test new collaboration models for the early drug development environment ( a focus of ACT) and will expand in 2017 to include Pre-Clinical through Clinical Trial phases, working towards identifying existing gaps where patient input could produce value.
The A Community Team (ACT): Redefining Research project was one of three innovation in research grant winners – and the only immunology winner - in Celgene’s 2015 Innovation Impact Awards. The main objective of this initial planning project was to test & facilitate innovative collaboration strategies between patients, researchers & industry in order to enhance engagement, improve treatment outcomes, and better utilize research dollars. A second objective was to engage with a larger, realistic sample of patients – instead of only including the typical patient advocate usually “at the table”, building the pool of future patient advocates and overall engagement opportunities. IFAA, an organization led by patients who have been “at the table” and who understand the physical and mental limitations associated with these diseases, led the design, research, and management with guidance from expert advisors.
The project focused strongly on the early drug development phase of the Research and Development (R & D) continuum. Diseases included in this initial pilot project included Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and/or Axial Spondyloarthropathy (axSpA). As the project continues (ACT II) it will expand to also include patients diagnosed with Rheumatoid Arthritis (RA) and/or Systemic Lupus Erythematosus (SLE) and will extend focus to include pre-Clinical Trial through Post Market Surveillance phases of the R & D continuum.
ACT II expansion will include:
Copyright 2017. All rights reserved. Information on this site is intended for informational purposes only Our foundation does not engage in the practice of medicine. Please consult a physician to obtain personal healthcare and treatment options. Tax ID: 27-1214308